Deutsches Leukämie-Studienregister
Studie: AMLSG 21-13

Öffentlicher Titel Dasatinib in patients with newly diagnosed Core-Binding Factor AML
Wissenschaftl. Titel Randomized Phase III Study of Intensive Chemotherapywith or without Dasatinib (Sprycel™) in Adult Patientswith Newly Diagnosed Core-Binding FactorAcute Myeloid Leukemia (CBF-AML)
Kurztitel AMLSG 21-13
Studiennummer KN/ELN LN_AMLSGU_2014_550
Studiengruppe AMLSG Ulm
Studienart multizentrisch, randomisiert, prospektiv, offen, zweiarmig
Studienphase Phase III
Erkrankung Akute myeloische Leukämie (AML) - AML alle außer FAB M3
Leukämiestadium de novo/non-treated - Genotyp-spezifische Therapiekonzepte - Alle Altersgruppen
Molekularer Marker CBF
  • To assess event-free survival (EFS) after intensive induction (daunorubicin and cytarabine) and consolidation (high-dose cytarabine) chemotherapy with or without dasatinib in patients with CBF-AML
  • To assess the interaction between type of CBF-AML [t(8;21) versus inv(16)] and randomization accordingly on all survival endpoints
  • To assess cumulative incidence of relapse (CIR) and death (CID)
  • To assess relapse-free (RFS) and overall survival (OS)
  • To assess outcome according toKIT mutational status
  • To assess pharmacodynamic inhibition of KIT
  • To assess toxicity
  • Both female and male patients meeting the inclusion and exclusion criteria will be included in this clinical trial, because the acquisition of an AML is independent of gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study
  • Core-binding factor (CBF) AML with molecular diagnosis of RUNX1-RUNX1T1 fusion transcript resulting from t(8;21)(q22;q22) (or a variant form) or of CBFB-MYH11 fusion transcript resulting from inv(16)(p13.1q22)/t(16;16)(p13.1;q22) as assessed in one of the two central AMLSG reference laboratories.
  • Age >= 18;there is no upper age limit
  • No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis if needed for up to 5 days during the diagnostic screening phase.
  • Non-pregnant and non-nursing. Due to the unknown teratogenic potential of dasatinib in humans, pregnant or nursing patients may not be enrolled. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration. Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control - one highly effective method (e.g., IUD, hormonal, tubal ligation, or partner’s vasectomy), and one additional effective method (e.g., latex condom, diaphragm, or cervical cap) - AT THE SAME TIME, at least four weeks before she begins dasatinib therapy and at least 3 months after last dasatinib administration. “Women of childbearing potential” is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months.
  • Men must agree not to father a child and must use a latex condom during any sexual contact with women of childbearing potential while taking dasatinib and for 3 months after therapy is stopped, even if they have undergone a successful vasectomy.
  • Signedwritteninformedconsent.
  • Performance status WHO >2
  • Pulmonary edema and/or pleural/pericardial effusion within 14 days of Day 1. If edema/effusion resolves to CTC Grade <= 1, patients can be treated with dasatinib.
  • Patients with ejection fraction < 50% by MUGA or ECHO scan within 14 days of day 1
  • Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or AP >2.5x upper normal serum level; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
  • Uncontrolledinfection
  • Severe neurological or psychiatric disorder interfering with ability of giving an informed consent
  • Patients with a “currently active” second malignancy other than non-melanoma skin cancers. Patients are not considered to have a “currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year.
  • Known positive for HIV, active HBV, HCV, or Hepatitis A infection
  • Bleeding disorder independent of leukemia
  • No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation.
  • Noconsentforbiobanking.
Alter Alle Altersgruppen
Status Aktiv
Beginn der Rekrutierung 22.07.2014
Fallzahl 277
Studienleiter/in Döhner, Prof. Dr. med., Hartmut
Kontaktperson f.
wissenschaftl. Anfragen
Döhner, Prof. Dr. med., Hartmut

Döhner, Prof. Dr. med., Hartmut
Tel: +49 (0)731 50045501
Fax: +49 (0)731 50045905

Organisatorische Anfragen
Paschka, Prof. Dr. med., Peter
Tel: +49 (0)731 500 45757
Fax: +49 (0)731 500 45905

Weimann, Stefanie
Tel: +49 (0)731 500 45914
Fax: +49 (0)731 500 45905

Kurzprotokoll Kurzprotokoll
Labore / Zentrale Diagnostik

Labor für Zytogenetische und Molekulargenetische Diagnostik, Klinik für Innere Med. III, Universitätsklinikum Ulm
Hämatologie, Hämostaseologie, Onkologie Hannover
Institut für Humangenetik, Medizinische Hochschule Hannover (MHH)

Sponsoren Universitätsklinikum Ulm
Förderer Universitätsklinikum Ulm
Bristol-Myers Squibb
Registrierung in anderen Studienregistern NCT02013648
erstellt 31.07.2014 Johannes Kraus
geändert 09.11.2015 Zenawit Krüger
© Informationszentrum im Kompetenznetz Leukämien | Ohne Gewähr für Richtigkeit oder Vollständigkeit | |